Home LiteratureArticle Details
PMID: 16537444 Published · ppublish English Journal Article

Structural characterization of autoinhibited c-Met kinase produced by coexpression in bacteria with phosphatase.

Wang W, Marimuthu A, Tsai J, Kumar A, Krupka HI, Zhang C, Powell B, Suzuki Y, Nguyen H, Tabrizizad M, Luu C, West BL

Abstract

Protein kinases are a large family of cell signaling mediators undergoing intensive research to identify inhibitors or modulators useful for medicine. As one strategy, small-molecule compounds that bind the active site with high affinity can be used to inhibit the enzyme activity. X-ray crystallography is a powerful method to reveal the structures of the kinase active sites, and thus aid in the design of high-affinity, selective inhibitors. However, a limitation still exists in the ability to produce purified kinases in amounts sufficient for crystallography. Furthermore, kinases exist in different conformation states as part of their normal regulation, and the ability to prepare crystals of kinases in these various states also remains a limitation. In this study, the c-Abl, c-Src, and c-Met kinases are produced in high yields in Escherichia coli by using a bicistronic vector encoding the PTP1B tyrosine phosphatase. A 100-fold lower dose of the inhibitor, Imatinib, was observed to inhibit the unphosphorylated form of c-Abl kinase prepared by using this vector, compared to the phosphorylated form produced without PTP1B, consistent with the known selectivity of this inhibitor for the unactivated conformation of the enzyme. Unphosphorylated c-Met kinase produced with this vector was used to obtain the crystal structure, at 2.15-A resolution, of the autoinhibited form of the kinase domain, revealing an intricate network of interactions involving c-Met residues documented previously to cause dysregulation when mutated in several cancers.

MeSH Terms
Amino Acid Sequence Base Sequence CSK Tyrosine-Protein Kinase Crystallography, X-Ray DNA/genetics Escherichia coli/genetics Gene Expression Genetic Vectors Models, Molecular Mutation Neoplasms/enzymology,genetics Phosphotransferases/biosynthesis,genetics Protein Structure, Tertiary Protein Tyrosine Phosphatase, Non-Receptor Type 1 Protein Tyrosine Phosphatases/genetics Protein-Tyrosine Kinases Proto-Oncogene Proteins/biosynthesis,genetics Proto-Oncogene Proteins c-abl/biosynthesis,genetics Proto-Oncogene Proteins c-met/antagonists & inhibitors,biosynthesis,chemistry,genetics Recombinant Proteins/antagonists & inhibitors,biosynthesis,chemistry,genetics src-Family Kinases
Chemicals
Proto-Oncogene Proteins Recombinant Proteins DNA Phosphotransferases Protein-Tyrosine Kinases Proto-Oncogene Proteins c-met CSK Tyrosine-Protein Kinase Proto-Oncogene Proteins c-abl src-Family Kinases CSK protein, human PTPN1 protein, human Protein Tyrosine Phosphatase, Non-Receptor Type 1 Protein Tyrosine Phosphatases
Authors & Affiliations
12 authors, click to expand affiliations / ORCID
Wang Weiru
Plexxikon, Inc., 91 Bolivar Drive, Berkeley, CA 94710, USA.
Marimuthu Adhirai
Tsai James
Kumar Abhinav
Krupka Heike I
Zhang Chao
Powell Ben
Suzuki Yoshihisa
Nguyen Hoa
Tabrizizad Maryam
Luu Catherine
West Brian L
References (50)
50 references, click to expand
  1. Novel mutation in the ATP-binding site of the MET oncogene tyrosine kinase in a HPRCC family.
    Int J Cancer. 1999 Aug 27;82(5):640-3 PMID: 10417759
  2. Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene.
    Cancer Res. 1998 Apr 15;58(8):1719-22 PMID: 9563489
  3. Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas.
    Oncogene. 2000 Mar 16;19(12):1547-55 PMID: 10734314
  4. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases.
    Proc Natl Acad Sci U S A. 2005 Aug 2;102(31):11011-6 PMID: 16046538
  5. Protein tyrosine phosphatase PTP-S binds to the juxtamembrane region of the hepatocyte growth factor receptor Met.
    Biochem J. 1998 Nov 15;336 ( Pt 1):235-9 PMID: 9806906
  6. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas.
    Nat Genet. 1997 May;16(1):68-73 PMID: 9140397
  7. Prevalence and clinical impact of Met Y1253D-activating point mutation in radiotherapy-treated squamous cell cancer of the oropharynx.
    Oncogene. 2003 Nov 20;22(52):8519-23 PMID: 14627992
  8. Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas.
    Cancer Res. 1999 Jan 15;59(2):307-10 PMID: 9927037
  9. The protein kinase complement of the human genome.
    Science. 2002 Dec 6;298(5600):1912-34 PMID: 12471243
  10. Two mutations affecting conserved residues in the Met receptor operate via different mechanisms.
    Oncogene. 2000 Mar 2;19(10):1354-61 PMID: 10713677
  11. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene.
    Cancer Cell. 2003 Apr;3(4):347-61 PMID: 12726861
  12. Met, metastasis, motility and more.
    Nat Rev Mol Cell Biol. 2003 Dec;4(12):915-25 PMID: 14685170
  13. Novel mutations of the MET proto-oncogene in papillary renal carcinomas.
    Oncogene. 1999 Apr 8;18(14):2343-50 PMID: 10327054
  14. The development of imatinib as a therapeutic agent for chronic myeloid leukemia.
    Blood. 2005 Apr 1;105(7):2640-53 PMID: 15618470
  15. Automated protein crystal structure determination using ELVES.
    Proc Natl Acad Sci U S A. 2004 Feb 10;101(6):1537-42 PMID: 14752198
  16. Met provides essential signals for liver regeneration.
    Proc Natl Acad Sci U S A. 2004 Jul 20;101(29):10608-13 PMID: 15249655
  17. A novel germ line juxtamembrane Met mutation in human gastric cancer.
    Oncogene. 2000 Oct 12;19(43):4947-53 PMID: 11042681
  18. Crystallography & NMR system: A new software suite for macromolecular structure determination.
    Acta Crystallogr D Biol Crystallogr. 1998 Sep 1;54(Pt 5):905-21 PMID: 9757107
  19. Improved methods for building protein models in electron density maps and the location of errors in these models.
    Acta Crystallogr A. 1991 Mar 1;47 ( Pt 2):110-9 PMID: 2025413
  20. Trisomy 7-harbouring non-random duplication of the mutant MET allele in hereditary papillary renal carcinomas.
    Nat Genet. 1998 Sep;20(1):66-9 PMID: 9731534
  21. Duplication and overexpression of the mutant allele of the MET proto-oncogene in multiple hereditary papillary renal cell tumours.
    Oncogene. 1998 Aug 13;17(6):733-9 PMID: 9715275
  22. Integration of macromolecular diffraction data.
    Acta Crystallogr D Biol Crystallogr. 1999 Oct;55(Pt 10):1696-702 PMID: 10531519
  23. Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-Met and its complex with the microbial alkaloid K-252a.
    Proc Natl Acad Sci U S A. 2003 Oct 28;100(22):12654-9 PMID: 14559966
  24. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571).
    Cancer Res. 2002 Aug 1;62(15):4236-43 PMID: 12154025
  25. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention.
    Cancer Lett. 2005 Jul 8;225(1):1-26 PMID: 15922853
  26. Targeting the tumor and its microenvironment by a dual-function decoy Met receptor.
    Cancer Cell. 2004 Jul;6(1):61-73 PMID: 15261142
  27. Refinement of macromolecular structures by the maximum-likelihood method.
    Acta Crystallogr D Biol Crystallogr. 1997 May 1;53(Pt 3):240-55 PMID: 15299926
  28. Met decoys: will cancer take the bait?
    Cancer Cell. 2004 Jul;6(1):5-6 PMID: 15261136
  29. Mutations in the met oncogene unveil a "dual switch" mechanism controlling tyrosine kinase activity.
    J Biol Chem. 2003 Aug 1;278(31):29352-8 PMID: 12746450
  30. Activation of the Met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice.
    J Cell Biol. 2001 May 28;153(5):1023-34 PMID: 11381087
  31. Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein.
    Mol Cell. 2001 Nov;8(5):995-1004 PMID: 11741535
  32. Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists.
    Oncogene. 1999 Sep 16;18(37):5221-31 PMID: 10498872
  33. A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design.
    Nat Biotechnol. 2005 Feb;23(2):201-7 PMID: 15685167
  34. The purification and characterization of the catalytic domain of Src expressed in Schizosaccharomyces pombe. Comparison of unphosphorylated and tyrosine phosphorylated species.
    Eur J Biochem. 1996 Sep 15;240(3):756-64 PMID: 8856081
  35. The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants.
    Oncogene. 2004 Jul 8;23(31):5387-93 PMID: 15064724
  36. Cancer therapy: can the challenge be MET?
    Trends Mol Med. 2005 Jun;11(6):284-92 PMID: 15949770
  37. c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions.
    Cancer Res. 2003 Oct 1;63(19):6272-81 PMID: 14559814
  38. Implementation of molecular replacement in AMoRe.
    Acta Crystallogr D Biol Crystallogr. 2001 Oct;57(Pt 10):1367-72 PMID: 11567147
  39. Activating Met mutations produce unique tumor profiles in mice with selective duplication of the mutant allele.
    Proc Natl Acad Sci U S A. 2004 Dec 7;101(49):17198-203 PMID: 15557554
  40. Regulation of the wild-type and Y1235D mutant Met kinase activation.
    Biochemistry. 2005 Nov 1;44(43):14110-9 PMID: 16245927
  41. Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog.
    EMBO J. 1997 Sep 15;16(18):5572-81 PMID: 9312016
  42. Crystal structure of the HGF beta-chain in complex with the Sema domain of the Met receptor.
    EMBO J. 2004 Jun 16;23(12):2325-35 PMID: 15167892
  43. Activating mutations for the met tyrosine kinase receptor in human cancer.
    Proc Natl Acad Sci U S A. 1997 Oct 14;94(21):11445-50 PMID: 9326629
  44. Novel somatic mutations of the MET oncogene in human carcinoma metastases activating cell motility and invasion.
    Cancer Res. 2002 Dec 1;62(23):7025-30 PMID: 12460923
  45. Activating mutations in the Met receptor overcome the requirement for autophosphorylation of tyrosines crucial for wild type signaling.
    Oncogene. 1999 Sep 9;18(36):5120-5 PMID: 10490849
  46. The Sema domain of Met is necessary for receptor dimerization and activation.
    Cancer Cell. 2004 Jul;6(1):75-84 PMID: 15261143
  47. K252a inhibits the oncogenic properties of Met, the HGF receptor.
    Oncogene. 2002 Jul 25;21(32):4885-93 PMID: 12118367
  48. A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family.
    Cell. 1994 Apr 22;77(2):261-71 PMID: 7513258
  49. Missense mutation of the MET gene detected in human glioma.
    Mod Pathol. 2000 Sep;13(9):973-7 PMID: 11007037
  50. Loss of the exon encoding the juxtamembrane domain is essential for the oncogenic activation of TPR-MET.
    Oncogene. 1999 Jul 22;18(29):4275-81 PMID: 10435641
Article Info
Journal
Proceedings of the National Academy of Sciences of the United States of America
Abbr.
Proc Natl Acad Sci U S A
ISSN
0027-8424
Published
2006-03-07
Epub
2006-00-28
Pages
3563-8
Language
English
Region
United States
NLM ID
7505876
PMCID
PMC1450123
Subset
IM
Databases
PDB
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com